Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Couper, Jennifer
ACTRN12613000794707: Why are more children getting Type 1 Diabetes? Exploring the environmental triggers islet autoimmunity and type 1 diabetes	Active, not recruiting	N/A	1500			University of Adelaide, National Health and Medical Research Council, JDRF Australia, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust	Type 1 diabetes
Tai, Andrew
SWIFT-2, NCT04718103 / 2020-003611-10: A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype Jul 2024 - Dec 2024 : H2'24 - Acceptance of regulatory submission in US (based on SWIFT-1 trial) for asthma	Completed	3	397	Europe, Canada, Japan, US, RoW	GSK3511294, Depemokimab, Placebo	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	04/24	04/24
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma	Recruiting	3	292	US, RoW	FF/UMEC/VI, ELLIPTA, FF/VI	GlaxoSmithKline	Asthma	01/27	01/27
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP	Active, not recruiting	3	1667	Europe, Canada, Japan, US, RoW	GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	10/25	10/25